Nathaniel P. Delos Santos

Nathaniel P. Delos Santos

Auto-generated profile, based on publicly available information

Nathaniel P. Delos Santos

Department of Biomedical Informatics, University of California San Diego , 9500 Gilman Drive, La Jolla, CA 92093-0634, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in Cell Stem Cell
Verified
Journal Article
Closed access
MZMaria Anna Zipeto
Maria Anna Zipeto
ACAngela C. Court
Angela C. Court
ASAnil Sadarangani
Anil Sadarangani
NSNathaniel P. Delos Santos
Nathaniel P. Delos Santos
LBLarisa Balaian
Larisa Balaian
CJCatriona H.M. Jamieson
Catriona H.M. Jamieson

1 November 2016 in Cell Stem Cell
Verified
Journal Article
Closed access
LCLeslie A. Crews
Leslie A. Crews
LBLarisa Balaian
Larisa Balaian
NSNathaniel P. Delos Santos
Nathaniel P. Delos Santos
HLHeather S. Leu
Heather S. Leu
ACAngela C. Court
Angela C. Court
CJCatriona H.M. Jamieson
Catriona H.M. Jamieson

1 January 2019 in Cancer Cell
Verified
Journal Article
Closed access
QJQingfei Jiang
Qingfei Jiang
JIJane Isquith
Jane Isquith
MZMaria Anna Zipeto
Maria Anna Zipeto
RDRaymond H. Diep
Raymond H. Diep
JPJessica Pham
Jessica Pham
CJCatriona Jamieson
Catriona Jamieson

1 October 2019 in Cell
Verified
Journal Article
Closed access
GBG. Stefano Brigidi
G. Stefano Brigidi
MHMichael G.B. Hayes
Michael G.B. Hayes
NSNathaniel P. Delos Santos
Nathaniel P. Delos Santos
AHAndrea L. Hartzell
Andrea L. Hartzell
LTLorane Texari
Lorane Texari
BBBrenda L. Bloodgood
Brenda L. Bloodgood

30 November 2015 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
FHFrida Holm
Frida Holm
EHEva Hellqvist
Eva Hellqvist
CMCayla N. Mason
Cayla N. Mason
SAShawn A. Ali
Shawn A. Ali
NDNathaniel Delos-Santos
Nathaniel Delos-Santos
CJCatriona H. M. Jamieson
Catriona H. M. Jamieson
Significance: In this study, we show for the first time, to our knowledge, that Muscleblind-like 3 (MBNL3) down-regulation in therapy-resistant human blast crisis leukemia stem cells (LSCs) is associated with activation of a human embryonic stem cell alternative splicing gene regulatory network involved in reprogramming and expression of a CD44 splice isoform, CD44 transcript variant 3. Targeting blast crisis LSCs with a human CD44 monoclonal antibody in combination with a potent breakpoint cluster region - ABL proto-oncogene 1, nonreceptor tyrosine kinase (BCR-ABL1) antagonist impairs LSC self-renewal in a niche-dependent manner and provides a compelling rationale for devising novel clinical combination LSC eradication strategies.

4 April 2016 in Scientific Reports
Verified
Journal Article
Open access
GPGabriel Pineda
Gabriel Pineda
KLKathleen M. Lennon
Kathleen M. Lennon
NSNathaniel P. Delos Santos
Nathaniel P. Delos Santos
FLFlorence Lambert-Fliszar
Florence Lambert-Fliszar
GRGennarina L. Riso
Gennarina L. Riso
CJCatriona H. M. Jamieson
Catriona H. M. Jamieson
While implicated in therapeutic resistance, malignant progenitor cell cycle kinetics have been difficult to quantify in real-time. We developed an efficient lentiviral bicistronic fluorescent, ubiquitination-based cell cycle indicator reporter (Fucci2BL) to image live single progenitors on a defined niche coupled with cell cycle gene expression analysis. We have identified key differences in cell cycle regulatory gene expression and transit times between normal and chronic myeloid leukemia progenitors that may inform cancer stem cell eradication strategies.